



**Glen Allen, Virginia 23060**

**(Address of principal executive offices) (Zip code)**

**(804) 205-5069**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

..Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

..Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

..Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

..Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

..

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 19, 2014, the shareholders removed Philip J. Young from the Board of Directors (the “Board”) of AmpliPhi Biosciences Corporation (the “Company”), effective immediately.

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On December 19, 2014, the Company held its special meeting of shareholders (the “Special Meeting”). The certified results of the matters voted upon at the meeting, are as follows:

The shareholders authorized an amendment to the Amended and Restated Articles of Incorporation of the Company allowing its Board, in its discretion at any time prior to June 30, 2015, to effect a reverse stock split of the Company’s outstanding common stock at a ratio at least five-for-one and up to fifty-for-one. The votes regarding this proposal were as follows:

| <b>For</b>  | <b>Against</b> | <b>Abstain</b> |
|-------------|----------------|----------------|
| 222,210,897 | 5,289,499      | 1,448,957      |

The shareholders approved an amendment to the Company’s Amended and Restated Articles of Incorporation modifying the requirements of director removal. The votes regarding this proposal were as follows:

| <b>For</b>  | <b>Against</b> | <b>Abstain</b> | <b>Broker Non-Votes</b> |
|-------------|----------------|----------------|-------------------------|
| 201,515,003 | 451,322        | 1,217,597      | 25,765,431              |

The shareholders removed Philip J. Young from the Board of the Company, effective immediately. The votes regarding this proposal were as follows:

| <b>For</b>  | <b>Against</b> | <b>Abstain</b> | <b>Broker Non-Votes</b> |
|-------------|----------------|----------------|-------------------------|
| 201,511,125 | 400,193        | 1,272,604      | 25,765,431              |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AmpliPhi Biosciences  
Corporation**

Date: December 24, 2014    By: /s/ David E. Boshier  
David E. Boshier  
Chief Financial Officer